Marc B. Garnick, MD, presented “The Prostate – Highlights of Prostate Cancer Advances As Covered in ASCO-SEP” during the 31st International Prostate Cancer Update in July 2021 in Snowbird, Utah.
How to cite: Garnick, Marc B. Einstein, David. “The Prostate – Highlights of Prostate Cancer Advances As Covered in ASCO-SEP.” July 2021. Accessed May 2024. https://grandroundsinurology.com/the-prostate-highlights-of-prostate-cancer-advances-as-covered-in-asco-sept-a-training-and-board-certification-program-for-medical-oncologists-worldwide/
The Prostate – Highlights of Prostate Cancer Advances As Covered in ASCO-SEP
Marc B. Garnick, MD, the Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, provides a capsulated summary of key references from the ASCO Self-Evaluation Program (ASCO-SEP) 7. He also distills information of interest for practice change related to urologic oncology, particularly prostate cancer, published over the last 12-18 months. Dr. Garnick covers topics including: the emerging role and trends of MRI following elevated PSA values; the introduction of the first oral GnRH antagonist (relugolix) for endocrine management of locally advanced, biochemical recurrence or de novo metastatic castration-sensitive prostate cancer; improvements in overall survival (OS) with the addition of androgen receptor antagonists to androgen deprivation therapy; and approvals of three drugs for improving metastasis-free survival and OS in non-metastatic castration-resistant prostate cancer. Dr. Garnick then reviews ASCO, European Association of Urology (EAU), and ASTRO guidelines published during the COVID-19 pandemic and concludes by sharing data from within the ASCO-SEP chapter on genitourinary cancers that offer a global perspective on mortality disparities for prostate, bladder, kidney, testicular, and penile cancers. He finishes the presentation by pointing out a “sobering” difference in mortality-to-incidence ratios, a parameter to estimate health system performance, between high- and low-to-middle-income countries worldwide.
About The 31st Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Garnick delivered this educational activity during the 31st iteration of the meeting in July 2021 in Snowbird, Utah.
